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Abstract
Aerosolized contrast agents may improve the resolution of biomedical imaging modalities and
enable more accurate diagnosis of lung diseases. Many iodinated compounds, such as diatrizoic
acid, have been shown to be safe and useful for radiographic examination of the airways.
Formulations of such compounds must be improved in order to allow imaging of the smallest
airways. Here, diatrizoic acid nanoparticle agglomerates were created by assembling nanoparticles
into inhalable microparticles that may augment deposition in the lung periphery. Nanoparticle
agglomerates were fully characterized and safety was determined in vivo. After dry powder
insufflation to rats, no acute alveolar tissue damage was observed 2 h post dose. Diatrizoic acid
nanoparticle agglomerates possess the characteristics of an efficient and safe inhalable lung
contrast agent.
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1. Introduction
Radiocontrast agents are medical contrast media aimed at improving the visibility of internal
body structures for imaging techniques such as magnetic resonance imaging, computed
tomography (CT) or radiography (X-ray imaging) (Barrs, 2006; Sanz and Fayad, 2008).
There are two basic types of X-ray contrast agents currently approved for human use;
barium sulfate and iodinated derivatives of benzene (Barrs, 2006). Barium sulfate
suspensions are used strictly for gastrointestinal (GI) tract imaging (Shook and Felson, 1970;
Tanomkiat and Galassi, 2000; Walsham and Larsen, 2008). Several iodinated contrast
agents have been safely used for many years without serious side effects. These compounds
increase the visibility of treated tissues and various iodinated molecules are used clinically
today (Ernst et al., 1998; Mukundan et al., 2006; Wisner et al., 1994).
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Contrast agents for CT examinations are administered by i.v. injection, oral dosing, or rectal
administration. Inhalation of contrast agents represents a relatively uncommon procedure.
Over the years, many efforts have been made to deliver contrast material to the lungs by
inhalation rather than by injection, but results have often been disappointing (Shook and
Felson, 1970). In addition, roentogenographic examination of the airways using the
conventional liquid contrast media has several disadvantages including poor aerosolization
efficiency and potential short residence times (Díaz-López et al., 2010; Fischer and Blaug,
1969; Nadel et al., 1968). More promising results have been obtained by inhalation of
powdered contrast media (mostly tantalum) (Nadel et al., 1968; Nadel et al., 1970; Scott and
Steiner, 1975); however, these formulations were not pursued because of the difficulty in
administration (Lafitte et al., 1982; Strecker et al., 1979), high cost, and lack of approval by
the FDA (Flower and Armstrong, 1986; Gamsu and Nadel, 1972).
A major problem with pulmonary delivery of aerosols is poor deposition efficiency as, in
some cases; < 10% of the inhaled drug powder reaches the alveoli (Bhavna et al., 2009;
Chan and Chew, 2003; Labiris and Dolovich, 2003; Telko and Hickey, 2005; Young et al.,
2007). To address this problem, a controlled nanoparticle agglomeration process has been
developed where particles exhibiting an aerodynamic diameter from 1 to 5 µm are created to
bypass the mouth and throat, resulting in augmented deposition in the lung periphery (Bailey
et al., 2008; El-Gendy et al., 2009; Plumley et al., 2009; Schoubben et al., 2010; Tsapis et
al., 2002). These porous agglomerates consist of closely-packed nanoparticles that may be
easily disseminated throughout the lung (El-Gendy and Berkland, 2009; Raffin et al., 2009;
Shi et al., 2007; Tsapis et al., 2002).
Diatrizoic acid, also known as amidotrizoic acid or 3,5-diacetamido-2,4,6-triiodobenzoic
acid, is an iodinated radiocontrast agent (Szmigielski et al., 1991a). Many investigations
have demonstrated safe and effective contrast enhancement when administrating powdered
diatrizoic acid by insufflation and inhalation methods for radiographic imaging of the
airways (Mcintire et al., 1998; Szmigielski et al., 1991b; Szmigielski et al., 1991a). Here,
diatrizoic acid nanoparticle agglomerates were formulated and characterized. Dissolution
studies were also performed for selected nanoparticles and nanoparticle agglomerates.
Finally, histological examination of rat lung tissue after dry powder insufflation was
performed to determine acute tissue damage.
2. Materials and methods
2.1. Materials
Diatrizoic acid anhydrous (Dia) and L-leucine (Leu) were purchased from Sigma Chemical
Co., St Louis, MO, USA. Ethanol, potassium dihydrogen phosphate (KH2PO4), disodium
hydrogen phosphate (Na2HPO4) and sodium chloride (NaCl) were purchased through Fisher
Scientific, Fair Lawn, NJ, USA. Floatable dialysis membrane units (regenerated cellulose
membranes manufactured from natural cellulose reconstituted from cotton linters, Mw cut-
off = 10,000 Da) were obtained from Spectrum Laboratories Inc., Rancho Dominguez, CA,
USA. Double-distilled water was used throughout the study, provided by an EASYpure®
RODI (Barnstead International, Model # D13321, Dubuque, Iowa, USA).
2.2. Preparation and characterization of diatrizoic acid nanosuspensions
Nanosuspensions were prepared using a precipitation technique. Briefly, solutions of
diatrizoic acid in ethanol were prepared at a concentration of 0.2% w/v and directly injected
into water at a rate of 1 mL/min. Various solvent/ non-solvent ratios were used under
ultrasonication (probe-type sonicator, Fisher Scientific, Sonic Dismembrator) operating with
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an amplitude of 48% or under homogenization (probe-type homogenizer, Tissue tearor,
Biospec Products, Inc.), as shown in Table 1.
The particle size and polydispersities of the nanoparticle suspensions were determined by
dynamic light scattering (Brookhaven, ZetaPALS, Holtsville, NY, USA). The same
instrument was used to determine the zeta potential of the nanoparticles in 1 mM potassium
chloride solution. Three runs of 15 cycles were acquired, and the mean zeta potential was
recorded. Some samples were frozen at −80°C and lyophilized at a temperature of −50°C
and under vacuum of 0.03 Mbar using a Labconco bench top lyophilizer (FreeZone 1,
Kansas City, MO). Drying lasted for 36 h to remove all appreciable water content.
Lyophilized powder was stored at room temperature for further characterization.
2.3. Agglomeration of diatrizoic acid nanoparticles
Nanoparticle colloids were destabilized via ionic interactions to control the agglomeration of
nanoparticles. Briefly, diatrizoic acid nanoparticle agglomerates were obtained by addition
of a flocculating agent, L-leucine powder. The amount of L-leucine added was adjusted to a
drug:leucine ratio equal to 1:1. Directly after addition, the suspensions were subjected to
vigorous mixing via homogenization at 25,000 rpm for 30 sec. The size of nanoparticle
agglomerates that were incubated with flocculating agent for 3 h was measured in Isoton
diluent using a Coulter Multisizer 3 (Beckman Coulter Inc.) equipped with a 100 µm
aperture. The flocculated suspensions were kept overnight at room temperature to allow
evaporation of ethanol and then frozen at −80°C before being lyophilized for further
analysis.
2.4. Characterization of the selected nanoparticle agglomerate
2.4.1. Particle geometric size and tap density measurements—The geometric size
and size distribution of the dispersed nanoparticle agglomerates as well as the resuspended
lyophilized powder were measured using a Coulter Multisizer™ 3.
Tap densities were determined for the dried powders and compared with that of the
diatrizoic acid powder as received. Fifty mg of powder was poured into a 10 mL graduated
measuring cylinder. The measuring cylinder was tapped vertically against a padded bench
20 times and the tap volume (Vt) was recorded. The process was repeated at least three times
and the average was taken. Tap densities (ρtap) of powders were calculated by dividing the
mass by the tapped volume recorded (Kumar et al., 2001; Staniforth, 2002).
2.5.2. Measurement of mass-median aerodynamic diameter
The theoretical mass–mean aerodynamic diameter (daero) of the nanoparticle agglomerates
was determined from the geometric particle size and tap density using the following
relationship (Chow et al., 2007; Vanbever et al., 1999b):
where dgeo = geometric diameter, γ = shape factor (for a spherical particle, γ = 1, the
particles in this study were assumed to be spherical), ρ = particle bulk density and ρref =
water mass density (1 g/cm3). Tap density measurements underestimate particle bulk
densities since the volume of particles measured includes the interstitial space between the
particles. The true particle density, and the aerodynamic diameter of a given powder, may be
expected to be slightly larger than reported (Fiegel et al., 2008).
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The aerodynamic size distributions of the agglomerate powders were measured directly from
lyophilized powders by time-of-flight measurement using an Aerosizer LD (Amherst
Instruments, Hadely, MA, USA) equipped with a 700 µm aperture operating at 6 psi. For
this step, ~5 mg of the powder were added to the Aerosizer and data were collected over ~60
sec under high shear force (~3.4 kPa).
2.5.3 In vitro aerosolization of nanoparticle agglomerates
Aerodynamic characteristics of selected nanoparticle agglomerates were studied using a
Tisch Ambient Cascade Impactor (Tisch Environmental, Inc., Village of Cleves, OH, USA).
The study was carried out by applying ~10 mg powder manually into the orifice of the
instrument at an air flow rate of ~30 L/min. Furthermore, the dry powders were resuspended
in water (1 mg/mL) and applied into the instrument through a nebulizer (PARI LC Star®
Reusable Nebulizer connected to compressor nebulizer system; PRONEB® Ultra II, PARI
Respiratory Equipment, Inc., Midlothian, VA, USA) for ~30 min at the same flow rate. Cut-
off particle aerodynamic diameters for each stage of the impactor were: pre-separator (10.00
µm), stage 0 (9.00 µm), stage 1 (5.8 µm), stage 2 (4.7 µm), stage 3 (3.3 µm), stage 4 (2.1
µm), stage 5 (1.1 µm), stage 6 (0.7 µm), stage 7 (0.4 µm) and filter (0 µm). Nanoparticle
agglomerates deposited on each stage of the impactor were determined by measuring the
difference in weight of filters placed on the stages. The percent emitted fraction (%EF) and
fine particle fractions of the total dose (FPFTD) were then calculated (Lechuga-Ballesteros et
al., 2008; Yang et al., 2008). The percent emitted fraction was determined from the
following equation:
The fine particle fraction of the total dose (FPFTD) was calculated as the percentage of
aerosolized particles that reached the lower seven stages of the impactor (corresponding to
aerodynamic diameters below 5.8 µm), or the lower five stages (corresponding to
aerodynamic diameters below 3.3 µm) according to the following equation:
In addition, the mass median aerodynamic diameter, MMAD, and geometric standard
deviation, GSD, were obtained by a linear fit of the cumulative percent less-than the particle
size range by weight plotted on a probability scale as a function of the logarithm of the
effective cut-off diameter (Pham and Wiedmann, 2001; Vanbever et al., 1999a).
2.6. Particle imaging
Nanoparticles and nanoparticle agglomerates were imaged via JEOL 1200 EXII
Transmission electron microscope to evaluate their size and morphology. Initially, carbon-
coated grids (Electron Microscopy Sciences) were floated on a droplet of the suspensions on
a glass microscope slide to permit the adsorption of the particles onto the grid. After this, the
grid was blotted with a filter paper and air dried for 1 h.
2.7. Thermal analysis
Differential scanning calorimetry (DSC) curves of diatrizoic powder as received,
nanoparticles and nanoparticle agglomerates were collected on a Q100 DSC from TA
Instruments using aluminum hermetic pans containing 2–5 mg of sample. Unless indicated,
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all DSC curves were collected from 25 to 400°C with a heating rate of 20°C/min under dry
nitrogen at 50 mL/min. The effect of heating rate on the peak transition was then observed
using DSC by heating the material at different heating rates (5, 10, and 20°C/min.).
Thermogravimetric analysis (TGA) was performed using a Q50 TGA from TA Instruments.
A platinum sample pan was loaded with ~5 mg of sample and heated from 25 to 400°C at a
rate of 10°C/min under dry nitrogen flow rate of 40 mL/min. Data analysis was completed
using Universal Analysis 2000 (Version 4.3A) software that was provided by TA
Instruments.
2.8. Process yield and loading efficiency measurements
After lyophilization, particle yield was determined using the following equation.
Diatrizoic acid loading efficiency in the dry powders was determined by dispersing 1 mg of
the lyophilized powder in 10 mL ethanol. The obtained suspension was sonicated in a bath-
type sonicator for 30 min and centrifuged at ~15,000 rpm for 30 min to remove insoluble
ingredients. Then, the amount of diatrizoic acid in the supernatant was determined
spectrophotometrically (Agilent C) at 238 nm. Drug loading was defined as follows:
2.9. Dissolution studies
The in vitro dissolution of diatrizoic acid from the prepared nanoparticles and nanoparticle
agglomerates was determined under sink conditions and compared with the dissolution
characteristics of the drug powder as received. An accurately weighed amount of the
lyophilized powder equivalent to 1 mg diatrizoic acid was dispersed in 10 mL phosphate
buffered saline (PBS, pH 7.4) and was suspended into a floatable dialysis membrane unit
(Mw cut-off = 10,000 Da). The unit was allowed to float in a beaker containing 350 mL PBS
and the whole assembly was stirred at a constant speed (100 rpm) using a magnetic stirrer
(Barnstead, Thermolyne MIRAK™) at 37 ± 0.5°C. Aliquots were withdrawn from the
dialysis bag and replaced with fresh medium at predetermined time intervals for a total
period of 8 h. Then, the drug content was measured using a reserved phase HPLC method as
described below. Studies were conducted in triplicate.
2.10. HPLC analysis of diatrizoic acid
Quantification of diatrizoic acid dissolution samples were analyzed using a reverse-phase
HPLC. The HPLC system consisted of a solvent delivery pump (Shimadzu LC-10AT), a
controller (Shimadzu SCL-10A), an autoinjector (Shimadzu SIL-10AxL), and a UV detector
(Shimadzu SPD-10A). The peak areas were integrated using Shimadzu Class VP (Version
4.3). The drug was separated on Phenomenex Synergi Hydro-RP C18 column (250 × 2 mm,
4 µm particle size). Standards and samples were prepared in MillQ water. Mobile phase
consisted of a mixture of methanol and 10 mM phosphate buffer (5:95 v/v), adjusted to pH
3.5 with phosphoric acid. Diatrizoic acid was eluted isocratically at a mobile phase flow rate
of 0.3 mL/min and monitored with a UV detector operating at 225 nm. The run time for the
assay was 10 min, and the retention time for the drug was 7.1 ± 0.2 min (Farag and Wells,
1997; Seitz et al., 2006).
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Female Sprague-Dawley rats (200–250 grams; Charles River Laboratories Inc., Wilmington,
MA, USA) were housed in temperature and humidity controlled rooms with free access to
food and water and maintained on a 12 h light/dark cycle. Rats were anesthetized by a 67.5
mg/kg ketamine, 3.5 mg/kg xylazine and 0.66 mg/kg acepromazine subcutaneous cocktail.
While under anesthesia, rats were placed on a heating pad to maintain a body temperature of
37°C. Diatrizoic acid nanoparticle agglomerates (10 mg) was administered by intratracheal
insufflation using a PennCentury DP-4 dry powder insufflator (Penn-Century Inc,
Philadelphia, PA, USA) using 3 mL of air. At the end of the experiment, the rats were
euthanized by isoflurane inhalation overdose followed by harvest of major organs. All
animal procedures were conducted according to guidelines approved by The University of
Kansas Institutional Animal Care and Use Committee.
2.12. Histology of Lung Tissue
Two hours post insufflation, rats were euthanized as described above and the lungs were
removed and stored in 10% neutral buffered formalin. Tissue samples were taken to the
pathology lab at Lawrence Memorial Hospital (Lawrence, KS, USA). At the lab, tissues
were embedded in paraffin wax and slices from the tissues were stained with hematoxylin
and eosin (H and E) dyes. The results of the tissues slides were discussed with a pathologist.
3. Results and discussion
3.1. Fabrication of diatrizoic acid nanoparticles
Various methods have been reported for generating nanoparticles of poorly water soluble
compounds. A precipitation method was selected to produce diatrizoic acid nanoparticles
(Bilati et al., 2005; Govender et al., 1999; Matteucci et al., 2006). Using this technique,
nanoparticle suspensions were designed with different ratios of ethanol and water as a means
to achieve a small particle size. Formulations prepared using 5/15, 5/25 and 2/28 solvent/
non-solvent ratios produced large particle sizes (up to 900 nm) when sonication or
homogenization was used during precipitation (Table 1).
Attempts to create diatrizoic acid nanoparticles using 1/29 ratio yielded reasonable particle
sizes (~145–188 nm) but offered very low nanoparticle yields. The most successful solvent/
non-solvent ratio and process for generating diatrizoic acid nanosuspensions was 2.5/25
using sonication (D9 on Table I). This formula demonstrated small particle size and was
selected for dry powder formulations. Only a slight change in zeta potential was observed
with different ratios of the solvents and the values ranged from 22–26 mV (Table 1).
3.2. Agglomerated diatrizoic acid nanoparticles yielded desirable aerosol characteristics
The mechanism to control nanoparticle agglomeration is mainly driven by leveraging the
competitive processes of attraction (van der Waals force) and repulsion (electrostatic
repulsive force, steric hindrance or both) (Kumar and Jain, 2007; Shi and Berkland, 2006).
The amino acid, L-leucine, was used as a flocculating agent in these studies. Leucine
destabilizes the diatrizoic acid colloid by masking the nanoparticle charge (Shur et al., 2008;
Young et al., 2002). Agglomeration produced ~2.4 µm particles consisting of closely-packed
diatrizoic acid nanoparticles. The average particle size of resuspended lyophilized powders
increased to some extent when compared to the nanoparticle agglomerates in suspension
prior to lyophilization (Table 2 and Fig. 1). This may be due to the deposition of
nanoparticles on agglomerates during lyophilization or to cohesion between agglomerates as
a result of drying (Shi et al., 2007).
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Tap density of the nanoparticle agglomerate powder was determined to be 0.05 ± 0.01 g/
cm3. This value was used for further calculations (Table 2). The main physical parameter
that predicts the site of aerosol deposition within the lungs is the aerodynamic diameter
(daero). The theoretical mass–mean aerodynamic diameter (daero) of the nanoparticle
agglomerate formulation as determined from the geometric particle size and tap density was
~1 µm (Table 2). Diatrizoic acid nanoparticle agglomerates with daero in this range may be
expected to reach the alveolar region of the lungs (Fiegel et al., 2004). The aerodynamic
diameter of the flocculated nanoparticles, measured by an Aerosizer LD, was ~1.2 µm
(Table 2 and Fig. 2). It was also clear that the aerodynamic size distribution was narrower
than the geometric size distribution (Fig. 1). When compared to the geometric diameter, the
lower aerodynamic diameter implied a low density for nanoparticle agglomerates.
Cascade impaction studies were carried out for both dry powder and resuspended dry
powder at an air flow rate of ~30 L/min (Fig. 3) and compared with that for drug as
received. Most nanoparticle agglomerates were deposited in stages 5–7 of the cascade
impactor which was indicative of efficient aerosolization and a high fine particle fraction.
On the other hand, the drug as received deposited mainly in the first stages whether it was
tested as dry powder or nebulized as resuspended powder. The aerosolization efficacy was
represented by the percent emitted fraction (%EF), fine particle fraction of the total dose
(FPFTD), mass-median aerodynamic diameter (MMAD) and geometric standard deviation
(GSD). The high emitted fraction of nanoparticle agglomerates obtained at the tested flow
rate (~76–88%) suggested efficient aerosolization of the powder. However, using the
nebulizer for delivering the resuspended dry powder achieved slightly higher percent
emitted fraction (Table 3). Cascade impaction data demonstrated that the anticipated total
lung deposition (i.e. FPFTD <5.8 µm) was about 93–96% and deep lung deposition (i.e.
FPFTD<3.3 µm) was ~80% for diatrizoic acid dry powder and resuspended formulation D9
delivered using a nebulizer. The formulated nanoparticle agglomerates had small mass-
median aerodynamic diameters (i.e. < 3 µm), which would make them suitable for deep lung
deposition. From the cascade impaction results (Table 3), the MMAD of D9 nanoparticle
agglomerates was determined to be ~1.5 µm. This experimental MMAD matched well with
the theoretical MMAD calculated from the tapped density (1.0 µm). The geometric standard
deviation (GSD) was determined using the equation:
where dn is the diameter at 15.87 and 84.13% for the cumulative distribution. The mass-
mean geometric size of the D9 agglomerates was 2.8 µm with a GSD of ~2.2 (Table 3).
3.3. Transmission Electron Microscopy
The investigated D9 nanoparticles exhibited a round shape and a diameter less than 200 nm
(Fig. 4A). TEM images of D9 nanoparticle agglomerates showed that the nanoparticles were
flocculated into micron sized agglomerates of approximately 2 µm resembling a collection
of round diatrizoic acid nanoparticles (Fig. 4B).
3.4. Thermal analysis
The DSC data of diatrizoic acid as received exhibited a broad endothermic event at 164.8°C
followed by an exothermic peak at 229.6°C and then another endothermic peak at 334.2°C
followed by subsequent degradation of the compound (Fig. 5). The early endothermic peak
may be suggestive of the dihydrate form of the compound and the second small observed
melting exotherm may be indicative of the dehydrated form of the molecule. The melting
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endotherm at 334.2°C may be evidence of the characteristic endothermic peak of the
anhydrous form of diatrizoic acid. In a similar experiment, the material was also heated from
25 to 270°C (the temperature prior to the characteristic peak of the drug) with a heating rate
of 20°C/min under dry nitrogen at 50 mL/min followed by cooling the powder to room
temperature using aluminum hermetic pans with holes. Then, the material was re-heated to
400°C at the same rate. This experiment demonstrated the disappearance of the first
endothermic and exothermic peaks and only the appearance of the sharp melting endotherm
at 334.2°C was observed (see supplementary Figure 1). These data support the hypothesis of
water loss from the hydrated compound. The effect of heating rate on these transitions was
then investigated using DSC by heating the material at different heating rates (5, 10, and
20°C/min.). These experiments (data not shown) revealed that the onset temperature of these
peaks did not significantly change. Also, TGA was performed on the material and a small
step change in TGA was started at 95.9°C leading to 4.2% loss at 114°C, which may
possibly be due to the loss of water from the compound. A large weight loss began at
308.5°C ended with a 55.7% loss at 335°C which could be attributed to the characteristic
endotherm of diatrizoic acid (Fig. 6).
The nanoparticles showed a very small and broad endotherm that began at 78.8°C
suggesting the presence of a small amount of residual water compared to the drug as
received (Fig. 5). The earlier appearance and the very small sharpness of the characteristic
melting endotherm (300°C) of the drug may be due to the small particle size (i.e. high
surface area) of the nanoparticles or, perhaps, to the presence of some surface defects or
amorphous material. This small peak immediately started to degrade. In addition, the curve
exhibited a small melting endotherm at ~300°C. A very low amount of residual solvent was
observed from the nanoparticles near 90°C by TGA (Fig. 6). Nanoparticles exhibited only
17.29% weight loss over the temperature range starting at ~320°C.
Diatrizoic acid in the nanoparticle agglomerates demonstrated a small and broad melting
endotherm at 79.8°C, which was slightly larger than the nanoparticles. This result also
suggested retention of a very small amount of solvent within agglomerates. Furthermore, a
very large endotherm began at 274.4°C, followed by subsequent degradation of the drug.
The shift of the characteristic melting endotherm of the drug in the nanoparticles
agglomerates may be due to large surface area that is retained in these particles. It may also
be attributed to the overlap of this peak with the sharp melting endotherm of L-leucine that
usually appears at 323.7°C. No significant mass loss was observed from the nanoparticle
agglomerates near 70°C by TGA (Fig. 6), reiterating that the lyophilization process removed
nearly all of the water. On the contrary, nanoparticle agglomerates showed a gradual
decrease in weight over this temperature range with a weight loss of 53% near 180°C
followed by a very high weight loss approaching 97.3% at 280°C. This may support the
hypothesis of degradation of the drug at higher temperature (Fig. 6).
3.5. Dry powder yield and loading efficiency of diatrizoic acid
The yield of the mass recovered for processed nanoparticle agglomerates was determined
(Table 2). The yield of nanoparticles agglomerates recovered as dry powders were
considerably high (~86%) which indicated efficient processing with minimum batch
variability. The loading efficiency of diatrizoic acid in the prepared nanoparticle
agglomerates D9 was found to be ~85% (Table 2), thus representing a negligible loss of
drug during preparation.
3.3. Dissolution studies of diatrizoic acid from the nanoparticles agglomerates
A dissolution study of diatrizoic acid was carried out for the prepared nanoparticles and
nanoparticle agglomerates and compared to the drug as received. The cumulative percentage
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of drug dissolved from nanoparticle agglomerates reached 100% after 2 h, which was slower
than that of nanoparticles which exhibited 100% after 90 min. On the other hand, the
dissolution behavior of diatrizoic acid from the nanoparticle agglomerates was faster than
that of the drug as received which required 4 h to dissolve completely. This finding was the
expected result of increasing the surface area by decreasing the particle size. Linear
regression analysis for the release data was done to determine the order of release. Zero-
order, first-order and Higuchi diffusion equations were applied to all dissolution results.
Linear regression analysis of the dissolution data concluded that the drug was released by
the Higuchi mechanism in all cases, as expected (Table 4). A two-way Analysis of Variance
(ANOVA) was performed to determine the significance of differences in diatrizoic acid
dissolution kinetics. Significant differences existed between nanoparticles, nanoparticle
agglomerates and diatrizoic acid powder as received. This suggested an improvement
(P<0.05) in the dissolution behavior of the nanoparticles and nanoparticle agglomerates
when these were individually compared to the diatrizoic acid powder as received.
3.4. Lung Tissue Histology
Histological examination of the lung tissue of rats that were insufflated with nanoparticle
agglomerates (10 mg) was compared to normal rat lung tissue to assess acute tissue toxicity
of the nanoparticle agglomerates. Since the insufflation technique may cause heterogeneous
drug distribution, both the left and right lungs were examined separately. No alveolar tissue
damage or inflammation was present throughout both the right and left lungs (Fig. 8). These
findings were in agreement with other studies showing diatrizoic acid safety after inhalation
(Szmigielski et al., 1991b;Szmigielski et al., 1991a). The results also indicated that there
was no acute toxicity associated with L-leucine, the flocculating agent.
4. Conclusion
Aerosolized radiocontrast agents may yield several advantages over conventional injection
of contrast media for improving airway examination if significant quantities can be safely
and effectively disseminated to the pulmonary bed. Diatrizoic acid is known to provide
substantial radiopacity and it is the root compound for many intravenous contrast agents on
the market today. Here, diatrizoic acid nanoparticle suspensions were successfully prepared
yielding ~136 nm nanoparticles without employing excipients. Nanoparticle suspensions
were agglomerated using L-leucine and dried to yield powders. Nanoparticle agglomerates
were efficiently aerosolized and offered a high fine particle fraction suitable for accessing
the peripheral lung. Nanoparticle agglomerates also exhibited faster diatrizoic acid
dissolution when compared to the stock powder. Histological examination of lung tissue
showed no acute toxicity or inflammation after insufflation of dry powder nanoparticle
agglomerates. Overall, diatrizoic acid nanoparticle agglomerates offered a promising
radiocontrast agent for safe and effective lung visualization.
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The particle size distributions of diatrizoic acid nanoparticle agglomerates D9 after
flocculation and resuspended after lyophilization.
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Aerodynamic size distributions of diatrizoic acid nanoparticle agglomerates D9 after
lyophilization.
El-Gendy et al. Page 14














The distribution of diatrizoic acid powder as received as well as nanoparticle agglomerate
formulation (D9) deposited on the stages of a cascade impactor at a flow rate of ~30 L/min.
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Transmission electron micrographs of diatrizoic acid A) D9 nanoparticles and B) D9
nanoparticle agglomerates.
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Differential scanning calorimetry (DSC) thermograms for diatrizoic acid as received,
nanoparticles (NP), nanoparticle agglomerates (NA) and L-leucine as received.
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Thermogravimetric analysis (TGA) for diatrizoic acid as received, nanoparticles (NP) and
nanoparticle agglomerates (NA).
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Dissolution profiles of diatrizoic acid in PBS (pH 7.4) from diatrizoic acid powder as
received, the prepared D9 nanoparticle (NP) and nanoparticle agglomerate formulation
(NA).
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Rat right lung histology images A) after 10 mg insufflation of D9 nanoparticle agglomerates
(2 h post dose) and B) normal lung tissue, no insufflation.
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Table 2
Characterization of diatrizoic acid nanoparticle agglomerates (NA) (values = average ± S.D.).
Characteristics Formulation (D9a)
Geometric particle size (µm) of NA before lyophilization 2.4 ± 1
Geometric particle size (µm) of lyophilized NA 2.9 ± 1
Tap density (g/cm3) 0.05 ± 0.01
MMADA b of lyophilized NA 2.1 ± 2
MMADt c of lyophilized NA 1.09 ± 0.1
Process yield of lyophilized NA (%) 86 ± 3
Loading Efficiency of lyophilized NA (%) 85 ± 4
a
D9 = 2.5/25 ethanol/water using sonicator
b
MMADA: Mass median aerodynamic diameter obtained from Aerosizer.
c
MMADt: Theoretical mass mean aerodynamic diameter calculated from density measurements
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Table 4
Modeling of release of diatrizoic acid from the prepared nanoparticles and nanoparticle agglomerates.




0.63 0.603 0.902 Higuchi
D9 nanoparticle
agglomerates
0.71 0.61 0.91 Higuchi
Diatrizoic acid
as received
0.786 0.69 0.92 Higuchi
a
D9 = 2.5/25 ethanol/water using sonicator
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